Domain-specific patterns of physical activity and risk of breast cancer sub-types in the MCC-Spain study

AbstractPurposeLiterature on the separate effects of physical activities (PA) on risk of breast cancer (BC) sub-types is heterogeneous. We investigated domain-specific associations between PA and BC risk by menopausal status and molecular subtype.Methods1389 histologically confirmed invasive BC cases and 1712 controls from the MCC-Spain study were included (age: 20 –85 years). Questionnaire information on PA at work, at home, and during leisure time, including recreational PA and sedentary time, and data on reproductive history, anthropometry, family history of BC, diet, and lifestyles were obtained through face-to-face interviews. Information on the expres sion of oestrogen (ER), progesterone (PR), and HER2 receptors was available for >  95% of the cases. Mixed-effects multivariable logistic regression models were used to estimate odds ratios (OR) of BC sub-types.ResultsOccupational PA (OPA) intensity was associated with higher BC risk. Associations were stronger for pre-menopausal (ORactive/very active vs. sedentary job 1.89; 95% confidence interval (CI) 1.22, 2.91) and ER+/PR+, HER2 − tumours (OR 1.80; 95% CI 1.28, 2.53). Sedentary time was associated with higher risk of post-menopausal BC (OR6 −9 vs.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research

Related Links:

AbstractBackgroundObesity carries a high risk of breast cancer with worse treatment outcome. Different molecular subtype and prognostic factors are linked to high body mass index (BMI) and affects overall and progression-free survival.MethodsAll 950 breast cancer patients presented to kasr Alainy oncology center (NEMROCK) from 2004 - 2014 at Al kasr alainy oncology center (NEMROCK) were followed up with a median period of 4.2years till Dec 2018. The body mass index (BMI) was assessed at diagnosis in 760 female patients. Disease-free survival (DFS) and overall survival (OS) were assessed and compared between three groups: n...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsCanadian pts represent a diverse population. Interim safety and efficacy results are generally consistent with the overall study: response rate - 21.1% for Canada v.s. 20.5% overall; clinical benefit rate - 66.1% Canada v.s 66.1% Overall, safety results were consistent with those observed in RIBO pivotal studies and no new safety signals were observed.Clinical trial identificationNCT02941926.Legal entity responsible for the studyNovartis.FundingNovartis.DisclosureC. Ferrario: Honoraria (self), Research grant / Funding (institution): Pfizer; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsInitial results from the Spanish cohort in CompLEEment-1 are consistent with previous data showing efficacy and a manageable safety profile of ribociclib plus letrozole as a first-line treatment option in a diverse group of patients with HR+, HER2 – ABC. Acknowledgement: Dr. J. Gavilá-Gregori, Dr. M.J. Martinez-Serrano and Dr. M. Perelló contributed equally to this study.Clinical trial identificationNCT02941926.Legal entity responsible for the studyNovartis Pharmaceuticals Corporation.FundingNovartis Pharmaceuticals Corporation.DisclosureE.M. Ciruelos: Advisory / Consultancy, Speaker Bureau /...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsThis interim analysis confirm the predictable and manageable safety profile of RIBO in combination with LET as first-line treatment for HR+, HER2 – ABC. The Italian C-1 cohort is the largest hormono-sensitive Italian population ever published with a CDK 4/6 inhibitor, including 6 male patients and 13 patients with CNS metastases that could give valuable information on this patient’s subgroups that still represent an unmet need.Clinical trial identificationEudraCT: 2016-003467-19, release date 2016-12-08 Protocol n. CLEE011A2404 NCT02941926.Legal entity responsible for the studyNovartis Pharma AG.Fund...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundOncotypeDX (ODX ®) can enhance prediction of breast cancer recurrence, guiding adjuvant treatment options. However, the opportunity to access this test is not always possible. The aim of this study is to investigate the correlation between phenotypical tumor characteristics, quantitative classical immunohistochemi stry (IHC) and recurrent score (RS) resulting from ODX®.MethodsAll breast cancer patients who underwent ODX ® between 2014 and 2018 were retrospectively included in the study. The data selected for analysis were age, menopausal status, pathological and IHC features. IHC was performed...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundApproximately 40% of pts with HR+, HER2 – ABC have mutations (mut) in PIK3CA, which encodes α-PI3K and leads to PI3K pathway hyperactivation and potentially ET resistance. ALP is a selective inhibitor of α-PI3K that, in combination with fulvestrant (FUL), significantly improved median progression-free survival (PFS) vs placebo + FUL i n pts with PIK3CA-mut, HR+ HER2– ABC in the phase 3 SOLAR-1 trial (11.0 vs 5.7 mo, respectively; HR 0.65; 95% CI, 0.50-0.85; P 
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundThe combination of a CDK4/6 inhibitor (CDK4/6i) with letrozole (LET) or fulvestrant (FUL) is the most active first –line (1L) treatment for patients (pts) with HR[+]/HER2[-] ABC. Although endocrine sensitivity persists beyond progression, preliminary findings suggest more adaptive resistance mechanisms to endocrine therapy (ET) than to CDK4/6i. At present, there are no data about prolonging CDK4/6 blockade bey ond progression on a CDK4/6i. The aim of this study is to determine whether palbociclib rechallenge combined with second–line ET upon progression to a prior palbociclib–based thera...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
This study will evaluate the efficacy and safety of olaparib plus trastuzumab in HER2[+] gBRCAm or wild–type gBRCA/HRD ABC pts.Trial designThis is a multicenter, single –arm, two–cohort, Simon’s two–stage, phase II trial. The cohort A will recruit N = 20 gBRCAm ABC pts. The cohort B will recruit N = 13 wild–type gBRCA/HRD ABC pts based on HRDetect assay. Pts will receive olaparib (300mg p.o. b.i.d. during 21–day cycles) in combination with trast uzumab (IV/SC at standard dose) until progression or unacceptable toxicity. Main selection criteria: (1) Pre&n...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundThe complexity of breast cancer (BC) at the clinical, morphological and molecular level has been well demonstrated. Molecular profiling, which reveals the intrinsic biology among subtypes, has significantly advanced the management of this disease. However, previous studies have provided very limited molecular data on Chinese BC patients.MethodsWe performed capture-based targeted sequencing on plasma samples using a panel consisting of 102 BC related genes, spanning 249  kb of human genome, to interrogate the genomic landscape of 236 female Chinese BC patients and compared our results to the TCGA da...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundAim: To clarify the clinicopathological characters and treatments and prognosis in elderly breast cancer patients using the Japanese Breast Cancer Registry (JBCR) system.MethodsWe reviewed data from JBCR, which is the nation-wide registry of newly diagnosed and operated primary breast cancer patients in Japan. To clarify its characteristics, we compared elderly patients aged 75 and over (elderly) with aged from 65 to 74 (young-old; y-o) and that from 55 to 64 (post-menopausal; p-m), respectively.ResultsIn total 132,240 cases diagnosed between 2004 and 2011 were reviewed (elderly; n  = 27,385...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Diets | HER2 | Men | Menopause | Nutrition | Spain Health | Study | Women